Education
About Us
Working with TipRanks
Follow Us
Emyria Ltd (AU:EMD)
:EMD
EMD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume148.47K
Average Volume (3M)316.24K
Market Cap
AU$17.68M
Enterprise ValueN/A
Total Cash (Recent Filing)AU$1.55M
Total Debt (Recent Filing)AU$802.68K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Sep 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding491,244,170
10 Day Avg. Volume712,677
30 Day Avg. Volume316,238
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)4.32
Price to Sales (P/S)0.00
P/FCF Ratio-17.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Emyria Ltd News
PremiumCompany Announcements
David Pevcic Ceases Substantial Holding in Emyria Ltd
PremiumCompany Announcements
Emyria Reports Positive Outcomes and Strategic Expansion
PremiumCompany Announcements
Emyria Expands Mental Health Services with New Empax Centre
PremiumCompany Announcements
Emyria Limited Issues New Shares for Immediate Trading
PremiumCompany Announcements
Emyria Limited Updates Director’s Interest with Strategic Share AcquisitionPremiumCompany Announcements
Emyria Ltd Issues Unquoted Equity Securities for Employee Incentive
PremiumCompany Announcements
Emyria Ltd Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Emyria Ltd Successfully Passes All Resolutions at Shareholder Meeting---
Options Prices
Currently, No data available
---
Ownership Overview
7.35% Insiders
―
Mutual Funds
― Other Institutional Investors
92.65% Public Companies and
Individual Investors
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$17.68M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 02, 2025 which is in 105 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2025. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 491,244,170 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
---
Emyria Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EMD Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.07%
12-Months-Change
Fundamentals
Return on Equity
-74.80%
Trailing 12-Months
Asset Growth
-19.03%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Ltd (EMD) is a healthcare technology and drug development company focused on advancing treatments for unmet medical needs through innovative research and clinical trials. The company operates within the healthcare and biotechnology sectors, offering a range of services that include drug development, data analytics, and clinical trials management. Emyria leverages proprietary data and technology to optimize patient outcomes and accelerate the commercialization of new therapies.
---
Technical Analysis
Biotron
―
Cynata Therapeutics Limited
―
Race Oncology Ltd.
―
IDT Australia Limited
―
---